Seeing hope: FDA panel considers gene therapy for blindnessABC NewsOn Thursday, U.S. Food and Drug Administration advisers will consider whether to recommend approval of a gene therapy that improved vision for these three youths and some others with he… Continue reading
Researchers create stem cell model of macular degenerationAOPScientists have used stem cells to create a model of macular degeneration for the first time. In a study published in Proceedings of the National Academy of Sciences, the University of Roches… Continue reading
FierceBiotech |
News of Note— A CAR–T for prostate cancer; targeting a faulty dementia gene; prompting cell suicide to treat leukemia
FierceBiotech San Diego-based Poseida Therapeutics is developing a chimeric antigen receptor T cell (CAR-T) therapy for prostate tumors that’s showing early promise in a particularly aggressive strain of the disease. Researchers at the company implanted human cell … |
FierceBiotech |
News of Note— A CAR–T for prostate cancer; targeting a faulty dementia gene; prompting cell suicide to treat leukemia
FierceBiotech San Diego-based Poseida Therapeutics is developing a chimeric antigen receptor T cell (CAR-T) therapy for prostate tumors that’s showing early promise in a particularly aggressive strain of the disease. Researchers at the company implanted human cell … |
|
US Stem Cell Inc (OTCMKTS:USRM) Could Be A Nice Recovery Play
Insider Financial US Stem Cell Inc (OTCMKTS:USRM) is a company that we have looked at on a few occasions over the last 12 months here at Insider Financial but it’s one that, over the last few months in particular, hasn’t had a particularly easy time in the markets. Investors Are Circling US Stem Cell, Inc. (OTCPK:USRM), What Do the Numbers Tell Us?MTNV ROE & Quant Signals in Focus For US Stem Cell, Inc. (OTCPK:USRM)Financial News Review |